CytoSorbents Corporation filed its Form 10-Q for the quarterly period ended September 30, 2026 with the U.S. Securities and Exchange Commission on November 19, 2026, reporting a net loss of $2.054 million for the third quarter and disclosing a 1-for-20 reverse stock split effected on September 8, 2026.

Key Highlights

  • Reverse stock split: A 1-for-20 reverse stock split was effected on September 8, 2026; all share and per-share amounts in the filing have been retrospectively adjusted.
  • Q3 net loss: The company reported a net loss of $2.054 million for the three months ended September 30, 2026, compared to a net loss of $3.170 million in the same period of 2025.
  • Nine-month net loss: For the nine months ended September 30, 2026, the net loss was $12.005 million, versus $2.701 million for the same period in 2025.
  • Q3 revenue: Net revenue for the third quarter was $9.728 million, up from $9.485 million in Q3 2025.
  • Stockholders' deficit: Total stockholders' equity (deficit) was $(2.309) million as of September 30, 2026, compared to positive $5.903 million as of December 31, 2025.
  • Long-term debt reclassified: Current maturities of long-term debt, net of debt discount, stood at $17.523 million as of September 30, 2026, reclassified from long-term, where $16.667 million had been reported as of December 31, 2025.
  • Shares outstanding: As of November 17, 2026, there were 3,152,889 shares of common stock outstanding.

CytoSorbents Reports Q3 2026 Results Following 1-for-20 Reverse Stock Split

According to the filing, CytoSorbents Corporation (NASDAQ:CTSO) reported net revenue of $9.728 million for the three months ended September 30, 2026, an increase from $9.485 million in the comparable prior-year quarter. Gross profit for the third quarter was $7.328 million, compared to $6.666 million in Q3 2025. Total operating expenses declined to $8.497 million from $9.528 million in Q3 2025, including $250 thousand in restructuring charges in the current quarter with no comparable charge in the prior-year period. The company reported a loss from operations of $1.169 million for the quarter, compared to $2.862 million in Q3 2025.

For the nine months ended September 30, 2026, the filing disclosed net revenue of $28.224 million versus $27.829 million in the same period of 2025. The nine-month net loss of $12.005 million was substantially wider than the $2.701 million loss reported for the first nine months of 2025. The filing identified a loss on foreign currency transactions of $2.534 million for the nine-month period in 2026, compared to a gain of $9.128 million in the same period of 2025, as a significant contributor to the difference in year-over-year results. Net interest expense for the nine months was $2.618 million, up from $1.866 million in the prior-year period.

The balance sheet as of September 30, 2026 showed total assets of $37.160 million and total liabilities of $39.469 million, resulting in a stockholders' deficit of $2.309 million. Cash and cash equivalents were $4.205 million, down from $6.249 million at December 31, 2025. The company also disclosed that the 1-for-20 reverse stock split, effected on September 8, 2026, resulted in retrospective adjustments to all share and per-share data throughout the filing. Basic and diluted net loss per common share for Q3 2026 was $(0.65), compared to $(1.01) in Q3 2025, both figures adjusted for the reverse split.

What Was Disclosed

CytoSorbents filed its quarterly report covering the period ended September 30, 2026, disclosing a Q3 net loss of $2.054 million, nine-month net loss of $12.005 million, a 1-for-20 reverse stock split effected September 8, 2026, and reclassification of long-term debt to current maturities totaling $17.523 million.